TC Biopharm (Holdings) Plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCBP research report →
Price Chart
About the company
Operating as a clinical-stage biopharmaceutical entity, TC Biopharm (Holdings) Plc is dedicated to pioneering immunotherapy solutions, leveraging its proprietary allogeneic gamma delta T cell platform. Its developmental portfolio includes OmnImmune, an unmodified cellular therapy aimed at acute myeloid leukemia, and ImmuniStim, another unmodified cellular therapy designed to combat COVID-19. The company was established in 2013 and is headquartered in Motherwell, United Kingdom.
- CEO
- Bryan Leland Kobel
- IPO
- 2022
- Employees
- 41
- HQ
- Motherwell, GB
Get TickerSpark's AI analysis on TCBP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $256.50K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.03
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -391.64%
- ROIC
- -246.60%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-14,239,323
- Net Income
- $-5,906,953-349.7%
- EPS
- $-188.09+51.0%
- OCF Growth
- +31.0%
- FCF Growth
- +31.4%
- 52W High
- $523.20
- 52W Low
- $0.08
- 50D MA
- $3.18
- 200D MA
- $48.27
- Beta
- 0.01
- RSI (14)
- 39
- Avg Volume
- 377.72K
No earnings-call transcripts are available for TCBP yet.
- Free Float
- 96.4%
- Shares Outstanding
- 2.56K
- Float Shares
- 2.47K
of shares held by institutions
5 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 30, 22 | Randall Diana Elizabeth | buy | 70,000 |
| Nov 30, 22 | Randall Mark Edward | buy | 70,000 |
| Nov 30, 22 | Randall Mark Edward | buy | 70,000 |
| Nov 30, 22 | Randall Mark Edward | buy | 70,000 |
| Nov 30, 22 | Randall Kenneth Edward | buy | 70,000 |
| Nov 30, 22 | Randall Kenneth Edward | buy | 70,000 |
| Nov 30, 22 | Randall Mark Edward | buy | 70,000 |
| Nov 30, 22 | Randall Mark Edward | buy | 70,000 |
| Nov 30, 22 | Randall Kenneth Edward | buy | 70,000 |
| Nov 30, 22 | Randall Kenneth Edward | buy | 70,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TCBP coverage
Recent articles, reports, and earnings notes.
No research on TCBP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TCBP report →TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
prnewswire.com · Jun 11
TCBP Announces Transition from Nasdaq to OTC Markets
prnewswire.com · Mar 21
TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
prnewswire.com · Mar 18
TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
prnewswire.com · Mar 5
TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
prnewswire.com · Feb 20
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
prnewswire.com · Feb 13
TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
prnewswire.com · Feb 10
TCBP to Implement ADS Ratio Change
prnewswire.com · Feb 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.